CSL Limited Annual Report 2021/22 26 5 Our Future Prospects The fundamentals of CSL’s business, including our talented people, strong platforms and leading products, position CSL to deliver growth over the long term. Our commitment to patients and to deliver innovative products is unwavering. As CSL looks ahead, the 2030 Strategy is designed to be resilient and allow us to better serve our patients well into the future, providing a strong platform for growth for shareholders. We focus on life saving therapies for people with rare diseases and on providing differentiated influenza vaccines that protect the health of populations. The underlying demand for our existing products in the core plasma, recombinant and vaccine platforms is driven by expanding markets and indications across geographies in each of our six therapeutic areas. The core plasma and influenza vaccines platforms have advantages that position us for growth over the long term, and provide competitive advantage over our peers. They deliver products that are complex to make, and require special skills that are not easily replicable. In addition, not all of our products are subject to patent protection and the subsequent revenue cliffs that can occur upon expiry. This allows us to sustainably grow our core business’ across therapeutic areas, platforms and geographies. The future prospects of our core business depend on having the right talent to execute our 2030 Strategy. As a purposedriven organisation, we are recognised as a great place to work because of our culture and values. It takes a unique mix of people to get the most out of our plasma business, grow our vaccines footprint and innovate the next generation of products. Given these strong advantages in platforms, products and people, the outlook for CSL is strengthening as we move beyond the COVID-19 pandemic. CSL’s platforms, products and people moving us beyond COVID-19 • The COVID-19 pandemic has affected the industry’s ability to collect plasma, which in turn has caused a tightness in supply of the end products and constrained the industry’s ability to fulfill patient demand. • Our plasma collection volumes have recovered to their prepandemic levels. Notwithstanding a long manufacturing cycle (typically 9-12 months) we expect the tightness in supply to alleviate throughout the rest of the calendar year. • Continued investments over the last few years, including expanding the collections network to over 300 centres and the rollout of the new Terumo plasma collection device, improve the donor experience and gives us a great position to capture growth opportunities, particularly in our leading HIZENTRA®/PRIVIGEN® immunoglobulin franchise. • Over the past two years, we have experienced strong demand for influenza vaccines as governments look to protect their health systems and populations, and to avoid a twindemic of COVID-19 and influenza. The demand profile is likely to continue to be robust as stakeholders recognise the benefits of population-level protection. • The acquisition of Vifor, upon closing, broadens our base with additional growth opportunities in iron replacement, dialysis and nephrology. Beyond our existing products, the R&D organisation is developing a portfolio of novel products to drive the next generation of growth. We are poised to launch our first gene therapy product, etranacogene dezaparvovec for haemophilia B, in the coming year and continue to develop novel monoclonal antibodies as well as next-generation technologies including aQIVc and sa-mRNA. In addition to novel products, our R&D efforts include expanding markets and indications for our existing products. These efforts provide new areas of growth across our therapeutic areas. Some examples are listed: • In the near term our gene therapy candidate, etranacogene dezaparvovec, is in the final stages of submission and if approved, will transform how haemophilia B patients are treated. • In the mid-termwe will endeavour to broaden our offering to patients with hereditary angioedema to include our recombinant monoclonal antibody, garadacimab. • Over the longer term, we have a number of innovative R&D programs in our pipeline such as CSL112, currently in development and aimed at reducing the risk of recurrent cardiovascular events. Our focus on extending and improving the lives of patients with rare and serious diseases has not wavered through the COVID-19 pandemic. In the future we may face a new set of challenges and opportunities that we must address to position us for growth over the long-term.
RkJQdWJsaXNoZXIy MjE2NDg3